Antimicrobial combinations are at the moment the only potential treatment option for
pandrug-resistant A. baumannii. A systematic review was conducted in PubMed and Scopus …

Purpose Pending approval of new antimicrobials, synergistic combinations are the only
treatment option against pandrug-resistant A. baumannii (PDRAB). Considering the lack of a …

The development and dissemination of antibiotic-resistant bacterial pathogens is a growing
global threat to public health. Novel compounds and/or therapeutic strategies are required to …

Fully ripe fruits and mature leaves of Elaeagnus angustifolia were harvested and analyzed
by means of analytical and biological tests to better comprehend the chemical composition …

Acinetobacter baumannii has emerged worldwide as a dominant pathogen in a broad range
of severe infections, raising an acute need for efficient antibacterials. This is the first report …

Many of the most common disinfectant and sanitizer products are formulations of multiple
antimicrobial compounds. Products claiming to contain synergistic formulations are …

Novel antimicrobials or new treatment strategies are urgently needed to treat Pseudomonas
aeruginosa (P. aeruginosa) related infections and especially to address the problem of …

The rapid emergence of antimicrobial resistance in Acinetobacter baumannii coupled with
the dried pipeline of novel treatments has driven the search for new therapeutic modalities …

Objectives Colistin resistance rates are rising globally among multidrug-resistant Gram-
negative bacilli, including Acinetobacter baumannii (A. baumannii). A new type of resistance …

Patients with severe carbapenem-resistant Acinetobacter baumannii (CRAB) infections
currently face significant treatment challenges. When patients display signs of infection and …